Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

The 2022 Tandem Meetings | Third-party virus-specific T-cells targeting 6 viruses post-BMT

Michael Keller • 23 Apr 2022
The 2022 Tandem Meetings
General

Michael Keller, MD, Children’s National Health System, Washington, DC, gives an overview of a study evaluating third-party virus-specific T-cells simultaneously targeting six different viruses following bone marrow transplantation (BMT). This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.

More from Michael Keller

Advances in off-the-shelf third-party T-cells for the treatment of infectious diseases post-BMT
1:56
Advances in off-the-shelf third-party T-cells for the treatment of infectious diseases post-BMT
Michael Keller • 23 Apr 2022
Third-party virus-specific T-cells for the treatment of refractory viral infections
1:13
Third-party virus-specific T-cells for the treatment of refractory viral infections
Michael Keller • 24 Apr 2022

Related Videos

Key principles for implementing AI tools into clinical practice
3:19
Key principles for implementing AI tools into clinical practice
Adrián Mosquera Orgueira • 24 Sep 2026
Current role of AI in hematology/oncology: separating the hype from reality
2:54
Current role of AI in hematology/oncology: separating the hype from reality
Adrián Mosquera Orgueira • 24 Sep 2026
Addressing the risk of over-reliance on AI in clinical decision-making
2:25
Addressing the risk of over-reliance on AI in clinical decision-making
Adrián Mosquera Orgueira • 24 Sep 2026
Telomere dynamics in normal and pathological aging
12:41
Telomere dynamics in normal and pathological aging
Coleman Lindsley • 18 Sep 2026
The content of VJHemOnc is intended for healthcare professionals